Agilent Media Briefing

AACR 2025 | April 27



Every Day Counts in the Race Against Cancer

Safe Harbor

This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company's goals, priorities, growth opportunities, customer service and innovation plans, new product introductions, financial condition and considerations, and the continued strengths and expected growth of the markets the company sells into, operations) **that involve risks and uncertainties that could cause results of Agilent to differ materially from management's current expectations.** The words "anticipate," "plan," "estimate," "expect," "intend," "will," "should" "forecast" "project" and similar expressions, as they relate to the company, are intended to identify forward-looking statements.

In addition, other risks that the company faces in running its operations include the ability to execute successfully through business cycles; the ability to successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross margin pressures; the risk that our strategic and cost-cutting initiatives will impair our ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties on our markets and our ability to conduct business; the impact of currency exchange rates on our financial results; the ability to improve asset performance to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix, and other risks detailed in the company's filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended October 31, 2024.

The company assumes no obligation to update the information in these presentations. This presentation include non-GAAP measures. Non-GAAP measures exclude primarily the impacts of asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, change in fair value of contingent consideration, loss on extinguishment of debt, business exit and divestiture costs, pension settlement loss and net gain on equity securities. We also exclude any tax benefits that are not directly related to ongoing operations, and which are either isolated or are not expected to occur again with any regularity or predictability. With respect to the company's guidance, most of these excluded amounts pertain to events that have not yet occurred and are not currently possible to estimate with a reasonable degree of accuracy. Accordingly, no reconciliation to GAAP amounts has been provided.

Today’s Presenters



Rita Shaknovich, MD, PhD
Chief Medical Officer,
Agilent Technologies



Sean Glenn, PhD
Vice Chair Molecular Pathology
Roswell Park Comprehensive Cancer Center

Robert Neely, PhD
Co-founder, Director and Chief Scientific Officer
Tagomics

Mark Garner, PhD
Director, Translational Research Segment,
Agilent Technologies

Rita Shaknovich, MD, PhD

Chief Medical Officer

Agilent
Trusted Answers

Agilent Vision

Transforming healthcare through innovation

Imagine a world where diseases like cancer are a thing of the past.

- Time counts ... so we're working tirelessly to help make that vision a reality.
- Biotechnology is not just about science; it's about changing lives. It’s about making healthcare more personalized, efficient, and effective, and ultimately improving patient care and outcomes.
- Today, we’ll share some of the latest advances that are contributing to this incredible future, one innovation at a time.

About Me

A physician scientist living in New York, NY



Education and Home

I received my medical training at the Mount Sinai School of Medicine in New York. I also completed my anatomic pathology residency and surgical pathology fellowship at Columbia Presbyterian Hospital in New York, and fellowship in Hematopathology at Weill Cornell Medicine. I live in New York City.

Professional Expertise and Experience

I have more than 20 years of experience in translational medicine and molecular diagnostics. The first part of my career was in academia as a diagnostic pathologist and head of a basic science laboratory at Weill Cornell Medicine, where I focused on the epigenetic mechanisms of carcinogenesis. For the last 10 years, I have been in the biotechnology industry, developing diagnostic tools for clinical use and supporting clinical trials.

Achievements

In my previous roles, I was extremely fortunate to be at the forefront of epigenetic research, making fundamental scientific observations regarding clonal evolution in cancer and supporting early companion diagnostic trials for immuno-oncology drugs. I also contributed to the development of the Galleri™ Multi-Cancer Early Detection liquid biopsy test. Additionally, I have published over 50 scientific articles in renowned journals and book chapters.

My Vision

Achieving great things together

“My vision for Agilent is to continue **pushing the boundaries of what's possible in biotechnology** by developing new tools to support research and clinical diagnostics.

Additionally, we aim to enable new treatments that can **revolutionize healthcare** through companion diagnostic tools.

I believe that **collaboration is the key** to achieving our goals, so I look forward to working closely with Agilent’s talented team, fantastic partners, and the broader scientific community.”

Why Agilent

Pushing the boundaries of what's possible

"I went through the long medical training, to achieve my MD PhD. Early on I cared for patients, some old, some young, and some who unfortunately succumbed to cancer. Their stories deeply touched me.

The resilience and courage they displayed in the face of adversity stayed with me, shaping my perspective and driving my passion. From that moment on, I dedicated my research work to cancer biology, determined to make a difference."

"I was drawn to Agilent because its mission to transform healthcare through innovation aligns perfectly with my own professional goals and personal values.

Agilent is at the forefront of biotechnology and companion diagnostics development and that's is incredibly exciting. I'm eager to contribute to the groundbreaking projects that are underway."

Agilent

Sean Glenn, PhD

Vice Chair Molecular Pathology

ROSWELL PARK COMPREHENSIVE CANCER CENTER

Agilent
Trusted Answers

Roswell Park and the Evolution of Clinical Genomics

Foundation & Expertise

Initiatives Central to Helping Our **Community Fight Cancer**

Contribution to the First Genome — 1990s-2003

Establishment of Genomics Facility — 1999- Today

The Center of Personalized Medicine — 2012

OmniSeq Precision Medicine — 2015

Advanced Molecular Diagnostics Initiative — 2022

MRD and Early Detection of Cancer



The Innovation Intersection – Essential for Success in Diagnostics



Innovation Intersection

- Integration of:
  - Medical and Scientific Need
  - Clinical Expertise
  - Leading-Edge Technology

Through Collaboration

- Leads to:
  - Clinical Trial Initiatives
  - Evolution & Dissemination of Testing
  - **Enhanced Patient Care**

The First Step in Any Collaboration: Identify the Problem

"If you find yourself in a fair fight, you didn't plan your mission properly."- Gen. David Hackworth

Investigators & Physicians

Comprehensiveness
- Diagnostics
- Prognostication
- Therapy
- Reporting

Speed
- WHO & ELN Guidelines

Don't Bill My Patient

Tests and procedures at diagnosis for a patient with AML

Tests and procedures	
Tests to establish the diagnosis	**Additional tests and procedures**
Complete blood count and differential count*	Complete physical examination[c]
Bone marrow aspirate†	Performance status (ECOG/WHO score)
Bone marrow trephine biopsy‡	Geriatric assessment[d] (optional)
	Biochemistry, coagulation tests[e]
	Hepatitis A, B, C; HIV-1 testing; CMV, EBV, HSV, VZV
Screening for gene rearrangements**	
• *PML::RARA, CBFB::MYH11, RUNX1::RUNX1T1, KMT2A* rearrangements, *BCR::ABL1*, other fusion genes (if available)	• 3-5 d
Additional genes recommended to test at diagnosis††	
• *ANKRD26, BCORL1, BRAF, CBL, CSF3R, DNMT3A, ETV6, GATA2, JAK2, KIT, KRAS, NRAS, NF1, PHF6, PPM1D, PTPN11, RAD21, SETBP1, TET2, WT1*	

• *FLT3, IDH1, IDH2*	• 3-5 d
• *NPM1*	• 3-5 d
• *CEBPA, DDX41, TP53; ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2*	• 1st cycle ~1 week

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN



https://www.mds-foundation.org/

Agilent

Molecular Pathology: How Can We Help The Front Line

“When leading the charge, I would rather be followed by a handful of lions over an army of sheep”

Regulatory Compliance

NEW YORK STATE OF OPPORTUNITY. | Department of Health | Wadsworth Center

A Comprehensive Guide to Achieving New York State Clinical Laboratory Evaluation Program Approval for Next-Generation Sequencing Assays

Phillip M. Galbo, Jr,* Robert F. Klees,† Blake Burgher,* Kiersten M. Miles,* Carl M. Morrison,* and Sean T. Glenn*



Technology & Lab Infrastructure



Clinical Content



Logistics



Acute Myeloid Neoplasms Genetics Panel (AML)								
DNA					RNA Fusion			
ABL1	CREBBP	JAK2	RUNX1	U2AF1	ABL1	FGFR1	MYH11	RARA
APC	DNMT3A	KIT	SF3B1	WT1	BCR	KMT2A	NUP214	RBM15
ASXL1	EZH2	KMT2A	SRSF2	ZRSR2	CBFB	MECOM	PDGFRA	RUNX1
ASXL2	FLT3	MECOM	STAG2		CREBBP	MKL1	PDGFRB	RUNX1T1
BCOR	IDH1	NPM1	TERT-Promoter		DEK	MLF1	PML	
CEBPA	IDH2	PHF6	TP53					

Chronic Lymphocytic Leukemia Genetics Panel (CLL)
DNA-Only Panel
ATM	NOTCH1
BCL2	PLCG2
BIRC3	SF3B1
BTK	TERT-Promoter
CKDN2A	TP53
CKDN2B	

Multiple Myeloma Genetics Panel (MM)		
DNA-Only Panel		
ATM	KRAS	CD47
BRAF	NRAS	FCRL5
CDKN2C	RB1	GPRC5D
CHEK2	STAT3	SLAMF7
DIS3	TERT-Promoter	TNFRSF17
EGR1	TP53	
IRF4	TRAF3	

Myeloproliferative Neoplasms Genetics Panel (MPN)				
DNA				RNA Fusion
APC	IDH2	NFE2	TET2	FGFR1
ASXL1	IKZF1	PPM1D	TP53	PDGFRA
CALR	JAK2	SF3B1	U2AF1	PDGFRB
CBL	KIT	SH2B3		ABL1
EZH2	KMT2C	SRSF2		BCR
IDH1	MPL	TERT-Promoter		

Acute Lymphocytic Leukemia Genetics Panel (ALL)						
DNA			RNA Fusion			
ABL1	IGH (non-chimeric Fusion)	RB1	BCR	ETV6	NOTCH1	TAL-1
CDKN1B	IKZF1	TERT-Promoter	ABL1	RUNX1	MYC	FGFR1
CDKN2A	JAK2	TP53	ABL2	TCF3	JAK2	NUP98
CDKN2B	MYC		CSF1R	PBX1	CRLF2	
CDKN2C	NOTCH1		PDGFRB	MLL (KMT2A)	EPOR	

Myelodysplasia Genetics Panel (MDS)								
DNA						RNA Fusion		
ABL1	DDX41	IDH1	PHF6	STAG2	U2AF1	CBFB	MYH11	RUNX1
APC	DNMT3A	IDH2	PPM1D	STAT3	WT1	CREBBP	NUP214	RUNX1T1
ASXL1	ETV6	JAK2	RUNX1	TERT-Promoter	ZRSR2	DEK	PML	
BCOR	EZH2	MPL	SETBP1	TET2		KMT2A	PRDM16	
CALR	FLT3	NPM1	SF3B1	TP53		MECOM	RARA	
CBL	GATA2	NRAS	SRSF2	UBA1				

Non-Hodgkins Lymphoma Genetics Panel (NHL)			
DNA-Only Panel			
BRAF	EPHA7	MAP2K1	TP53
BIRC3	EZH2	MYD88	TRAF2
BTK	IDH2	PLCG2	CREBBP
CXCR4	IGH (non-chimeric Fusion)	TERT-Promoter	KMT2D
DNMT3A	MEK	TET2	TNFAIP3

Agilent

Strategic Partner with Shared Core Values to Close the Loop

Teamwork makes the dream work – John C. Maxwell

SureSelect XT HS2 Target Enrichment System/Reagents

Agilent Automation Solutions





Agilent | Trusted Answers

QIAGEN

Qiagen QSA-QCI Clinical Reporting



Agilent

Successful Collaboration to Create the SureSelect Cancer Pan Heme Assay

Democratized access to comprehensive genomic profiling of hematologic malignancies



2.6 Day Turn-Around Time

Direct EHR/Cerner Ordering



Magnis Automated Lab Workflow

Qiagen Driven Automated Analysis



Direct EHR Reporting



First Agilent on site visit: 08/22 → Weekly Strategy and Development Meetings → Full Solution Available 2025

SureSelect Cancer Pan Heme Assay – Best on Market!

Comprehensive Rapid NGS Testing Solution for Heme Malignancies

	Test 1	Test 2	Test 3	PanHeme
Turn-Around Time	48hrs	5 day	~2 weeks	~60hrs
SNVs	✓	✓	✓	✓
Indels	✓	✓	✓	✓
ASXL1 homopolymer	✗	✓	✓	✓
CALR	✗	✗	✓	✓
FLT3 ITD (including >150bp)	✗	✓ ✗	✓	✓
Chimeric Fusions	✓ ✗	✓	✓	✓
Non-Chimeric IGH Fusions	✗	✗	✓ ✗	✓
Risk Stratification (large SV)	✗	✗	✓ ✗	✓
Inherited Indications	✗	✗	✗	✓
Comprehensive Molecular Profile	✗	✗	✗	✓

Existing Market

Emerging Market

Speed and Comprehensiveness are Essential

From Roswell to the Masses

Providing This Rapid Comprehensive Solution Globally



* Divided by 80 for scale



The A-Team: The Three Amigos

Roswell–Agilent–Qiagen

Team Leaders:

Carl Morrison, MD, DVM

Phillip Galbo, PhD

Prashant Singh, PhD

Advanced Molecular Lab:

Blake Burgher
Kiersten Marie Miles, PhD
Lily Granville
LeeAnn Tindell
Lujain Ar-rawi
Ashley Mingo
Sirinapa Szewczyk
Melissa Mallon
Vincent Giamo
Jesse Luce
Christian Borrelli
Bailey Stark, MPA

IT & Informatics:

Chris MacDonald
Abhi Pughazhendhi
Ben Plessinger
Joe Lee

Ronda Allen
Heidi Kijenski
Kelle Hammock
Edward Jan
Mike Ruvolo
Gregory Miles
Marco Chiapello
Eric Lin
Linus Forsmark
Katherine Wilkins
Mustafa Shafiq
Doug Roberts
Supriya Swarnkar
Phil Klimball
Kevin Meldrum
Sam Raha

Brendan Burns
Chelsea Alexander
Bryony Brown
Neha Jalan
Kim Madsen
Nelson Vila
Vignesh Brahmadesham

Robert Neely PhD

Co-founder, Director and

Chief Scientific Officer

TAGOMICS

Agilent

Trusted Answers

Introducing Tagomics

Tagomics is a pioneering **biomarker discovery and diagnostics** company based in Cambridge, UK. Founded in 2021 as a spin-out from The University of Birmingham.

Tagomics has developed a **novel multiomics platform** called Interlace™. This platform offers a seamless solution for multiomic profiling, which integrates:

Epigenomics – studying chemical 'switches' on the genome

Genomics – detecting mutations and other structural variants

Fragmentomics – the analysis of DNA fragmentation patterns in the blood.

Interlace is designed to **unlock disease-associated DNA biomarkers**, providing **unparalleled biological insights** for biomarker discovery, diagnostic development, and precision medicine applications.

Tagomics is part of Agilent's Early-Stage Partnership program, which supports innovative startups with investment and consultation.

Tagomics' ambition is to make multiomics simple



Patient blood contains multiple biomarkers of disease

Genetics, DNA methylation, unique DNA fragmentation patterns, RNA levels, protein and metabolomic markers

Current lab processes are ill-suited for multiomic analysis

Each biomarker requires a distinct process, analysis

Our aim:

- Single sample input
- Non-damaging process
- Derive as much data- for the benefit of the patient- as possible

Tagomics' Novel Approach To Epigenetic Profiling: Activace

Tagomics' unique enzyme and helper molecule target specific DNA regions without causing damage, making the process efficient and precise and preserving the biosample



World's first platform for targeted, highly-specific enrichment of unmethylated DNA

Enzymatic chemistry, leveraging nature's solution to targeted DNA modification:

- Non-damaging
- Compatible with minute input amounts of DNA
- A foundation for a streamlined multiomic workflow

Interlace™: An Integrated Multiomic Workflow

Preparing and tagging DNA in one step, from a single input sample. Interlace allows simultaneous genetic and epigenetic readout, identifying important and additive biomarkers.



Single-pot library preparation and tagging of unmethylated DNA

Enrichment of unmethylated DNA and mutation hotspots

Sequencer agnostic

Multiomic biomarker identification

Interlace+SureSelect CGP: Plug-and-play multiomics

Interlace seamlessly integrates with Agilent's SureSelect library preparation and SureSelect Comprehensive Genomic Profiling panel to enable feature-rich, multiomic genome profiling.



- Epigenetics
- Targeted mutations
- Fragmentomics
- Whole genome sequencing



Interlace+SureSelect delivers unparalleled multiomic insights for biomarker discovery, diagnostic development, and precision medicine applications.

Validated on over 130 samples (Inc. Cell lines / NAT / Tumour / cfDNA)

Interlace+SureSelect CGP: Input requirement

Profiling the epigenome from minute amounts of sample. More information from difficult samples.





Validated in partnership with Agilent Technologies: Robust epigenomic profiling from as little as 1 ng DNA input

Integration of SureSelect library preparation with Tagomics epigenomic enrichment enables genome-wide, epigenomic profiling with as little as 1 ng of input DNA. (Left) Genome-wide Spearman correlation of the epigenomic profile (to the profile created with 50 ng input), with decreasing amounts of input DNA. (Right) Screenshots from the genome browser (IGV) showing Tagomics' Activace profiles for unmethylated DNA, with decreasing input amount.

Interlace+SureSelect CGP: Validation of the epigenomic output

Matching the gold-standard in epigenomic profiling with 1/10th the sequencing costs

Comparison of the Interlace epigenomic profile to bisulfite data

Top: Whole-genome bisulfite sequencing for DNA derived from the HEK293 cell line (750M reads). Blue traces: Tagomics' epigenomic signal shows consistent mirroring of the whole-genome bisulfite sequeincing data across this region of interest. Tagomics' signal has been downsampled to 50M reads and is typically 90% saturated at 70M reads enabling low cost, genome-wide epigenomic profiling.

Non-damaging enzymatic enrichment

Targeting unmethylated CpG sites, allows reproducible, genome-wide profiling with 70M reads.

Highly-specific, efficient enzymatic enrichment

Enrichment over background in excess of 100x. Covalent DNA modification, streptavidin pulldown.

Enzymatic targeting of the active genome

Unmethylated promoters and enhancers, hypomethylated DNA. A unique, assumption-free profile targeting key biology.

Interlace+SureSelect CGP: Validation of the genetic output

Providing detailed genetic information, helping to select the best therapy for patients

Single-nucleotide variant calling with performance consistent with the SureSelect CGP panel alone



Validated in partnership with Agilent Technologies

Integration of SureSelect library preparation and hybridization panel - (Left) Genome-wide Spearman correlation of the epigenomic profile (to the profile created with 50 ng input), with decreasing amounts of input DNA. Genome-wide profiling is feasible with sub-nanogram inputs. (Right) Spearman correlation of the variant allele fractions determined for an analytical standard (Oncospan gDNA) using Tagomics Interlace (multiomic) workflow with Agilent's Sure Select CGP panel integrated into the workflow, and Agilent's Sure Select CGP panel alone.

100% concordance Interlace <> CGP panel alone

The Interlace workflow allows **SNV profiling with high fidelity,** directly comparable to running the CGP panel alone.

97.7% of known variant alleles found

For the reference Oncospan DNA **247 of 253 known variants were found using Interlace at a mean read depth ~125x.** The six missed all had VAF < 3%

Interlace+SureSelect CGP: Key platform properties

Single sample input, cost-effective sequencing requirement, detailed multiomic profiling output

Highly efficient enzymatic enrichment

Enrichment over background in excess of 100x. Covalent DNA modification, streptavidin pulldown for epigenomic profiling.

Base-conversion-free enrichment

Simple sequencing alignment. Preserves genomic DNA sequence for analysis with the Agilent SureSelect CGP panel.

Comprehensive genetic and epigentic profiling in a single-sample workflow

Unmethylated promoters and enhancers, hypomethylated DNA. A unique, assumption-free profile targeting key disease biology. **Complementary read-out of genetic abnormalities**.

1/10th sequencing requirement of WGBS

Targeting unmethylated CpG sites, allows reproducible, genome-wide profiling with 70M reads.

Tailored for discovery

Comprehensive genetic signature of disease captured by SureSelect CGP panel**. Low cost epigenomic profile** facilitates broad understanding of disease biology.

Scalable, genome-wide epigenomic profiling

Sequencing cost in the region of $200 per human epigenome allows seamless transition between discovery and deployment of the test.

Lung cancer biomarker discovery

Identifying changes in DNA methylation between cancerous and normal tissues, helping discover biomarkers for lung cancer

Interlace+SureSelect CGP: Epigenomic signature for lung cancer

Linking changes in DNA methylation to specific genes and pathways, helping to understand lung cancer biology



Hypermethylation



Hypomethylation

Differential methylation in cancer

Differentially methylated regions (DMRs) can robustly be identified by simple comparison of profile signals in tumour and normal adjacent tissue (FFPE samples).

Example with 6 lung cancer patients

Interlace epigenomic profiles used to identify **both hyper- and hypomethylated** regions of the genome in all tumours

Over a hundred thousand differentially methylated regions

Genome-wide, we capture significant changes in methylation associated with tumour biology.

Interlace+SureSelect CGP: Epigenomic signature for lung cancer

Changes in methylation status occur in regions associated with known cancer pathways



DMR enrichment analysis

DMRs are linked to closest gene (+/-3kb from TSS) for pathway enrichment analysis using the KEGG database

Plot of DMR enrichment vs p-value

DMRs linked with genes that are associated with established lung cancer biology are highly enriched in this cohort of six patient tumours.

Lung cancer specific and more general pathways identified

Methylation is disrupted in genes associated with known lung cancer pathways, as well as in more general cancer pathways

Interlace+SureSelect CGP: Genomic signature for lung cancer

Read out of genetic mutations allows targeted and personalized therapy selection

Summary of single nucleotide variants and tumour mutational burden (TMB) called in tissue (FFPE blocks) for six lung cancer patients



SureSelect CGP panel enables genetic biomarker discovery

Targets 679 cancer-associated genes as well as TMB, SNVs, CNVs, MSI… Sequenced to a mean 600x.

Critical information for therapy selection

Interlace+SureSelect CGP enables comprehensive view of genome biology and subsequent targeting of diagnostic tests.

Streamlined workflow, one sample, two readouts

SureSelect CGP ideal for discovery, can be switched for a more targeted panel when biomarker is defined.

Interlace+SureSelect CGP: Larger cohort of lung cancer patients

A larger cohort of lung cancer patients shows consistency of epigenomic signal, highlights most significant changes in disease



Unsupervised clustering on unseen cohort

Differentially methylated regions have consistent signal across a larger cohort of lung cancer patients (21 vs 18)

A basis for tumour-naïve diagnostics

ctDNA with tumour-specific methylation can be detected in background of cfDNA.

For diagnostics, leverage the breadth of (epi)genomic signal

Signal from multiple readouts can be aggregated to make diagnostic decisions, based on wholistic view of the (epi)genome.

Interlace+SureSelect CGP: Information-rich biomarker discovery

Tagomics' epigenomic profile

Using nature's solution to targeting the epigenome with a unique focus on unmethylated CpG sites.

One sample, two outputs

Genetic profile for personalized therapy selection.
Epigenetic profile for added sensitivity and biological context.

Agilent SureSelect Library Preparation

Highly efficient library preparation, optimized for SureSelect panels

Highly-specific, efficient enzymatic enrichment

Enrichment over background in excess of 100x. Covalent DNA modification, streptavidin pulldown.

Agilent SureSelect CGP panel

Comprehensive genomic profiling for biomarker discovery

1/10th sequencing requirement of WGBS

Targeting unmethylated CpG sites, allows reproducible, genome-wide profiling with 70M reads.

Mark Garner, PhD

Director, Translational Research Segment

From predicting the future of earth's climate, to developing new cancer therapeutics, all scientific understanding begins with measurement

Agilent enables researchers to make the measurements they need, by delivering cutting-edge, accessible, end-to-end solutions to help solve compelling scientific problems.

LC & MS-Based Metabolomics and Proteomics Solutions

NGS Library Preparation and Target Enrichment Technology for DNA and Gene Expression

Cancer cell Metabolic Profiling

Quantitative Immunophenotyping and Proliferation Assays

Real-Time Live-Cell widefield and confocal imaging with Image Analysis

SureSelect Target Enrichment Cancer CGP Assay

Custom Antibodies, Beads and Reagents



Companion Diagnostic Solutions

End-to-End Staining and Digital Pathology Workflows

Basic research | Translational research | Dx and treatment



265,000

analytical labs globally use Agilent solutions

Agilent's cancer mission is to provide the technology and solutions researchers and clinicians need throughout the cancer continuum

Uncover	Discover	Translate	Enable	Deliver	Fight
How cancer cells behave and avoid the immune system	The genetic changes which drive cancer	Advance discoveries from basic to clinical research	The diagnosis with trusted pathology solutions	Precision diagnostics to help guide therapeutic decision making	Drive cutting edge molecular and cellular therapies
					

Agilent's comprehensive portfolio of cancer solutions and workflows empower scientific and medical professionals from bench to bedside ... and back

LC & MS-Based Metabolomics and Proteomics Solutions

NGS Library Preparation and Target Enrichment Technology for DNA and Gene Expression

Cancer cell Metabolic Profiling

Quantitative Immunophenotyping and Proliferation Assays

Real-Time Live-Cell widefield and confocal imaging with Image Analysis

SureSelect Target Enrichment Cancer CGP Assay



Custom Antibodies, Beads and Reagents



Companion Diagnostic Solutions

End-to-End Staining and Digital Pathology Workflows

Basic research | **Translational research** | **Dx and treatment**

The Agilent Seahorse Analyzer transformed cancer metabolism research

Ever since Otto Warburg's initial studies (almost exactly) 100 years ago, it has been known that **cancer cells are profoundly different from the normal cells from which they are derived,** even at the level of fundamental cellular physiology.

The Seahorse Analyzer enabled scientists to quantitatively measure cellular metabolism like never before.



" If one wants to really understand the basis of the growth of tumors, it is necessary to first and foremost, focus on the chemical reactions which support that growth, the *energy producing* reactions."

- Otto Warburg, Biochemische Zeitschrift 1923

Announcing the new Agilent Seahorse XF Flex Analyzer

Seahorse XF Flex Analyzer

XF Flex 3D Capture Microplate and 3D MST Kit

XF Flex 3D Tissue Workflows



Broaden the Spectrum of Real-Time Metabolic Analysis

From 2D cell cultures to translationally relevant 3D models

Agilent

Cancer biomarkers continue to evolve – and so do we

From the Philadelphia chromosome as a (visible) biomarker for Chronic Myeloid Leukemia (CML)

to

Targeted disease-specific genomic profiling panels

and

Multiomics and epigenomics





Partnering for pathbreaking innovation





ROSWELL PARK COMPREHENSIVE CANCER CENTER



TAGOMICS

Agilent

Booth # 2036

Let’s bring **great science** to life.

Questions

Rita Shaknovich

Sean Glenn

Robert Neely

Mark Garner

Agilent

Trusted Answers